miércoles, 7 de octubre de 2026
BuscarExplore
Via News Knowledge File

U.S. Securities and Exchange Commission

government agency80% conf.·synced Oct 7, 2026

U.S. federal regulatory agency overseeing securities markets

0
sourced metrics
1710
relationships
8
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Stated objectives

Make the U.S. the crypto capital of the world

source
stated

Incorporate crypto into retirement programs through regulatory guidance

source
target: regulatory framework by 2026-01-01 00:00:00stated

Provide whistleblower rewards totaling up to 30% of any successful recovery for original information

source
target: 30 stated

Work toward allowing the inclusion of alternative assets in self-directed retirement plans

source
stated

Encourage whistleblowers to provide original information about securities violations through rewards program offering up to 30% of successful recoveries

source
target: 30 stated

SEC Whistleblower program incentivizing persons with non-public information about Hercules Capital securities violations to come forward with original information in exchange for monetary rewards

source
target: up to 30% of successful SEC enforcement recovery stated

Cut off opportunities for market manipulators to exploit small overseas IPO listings and protect mom-and-pop investors from pump-and-dump schemes.

source
stated

Establish dedicated crypto custody rules for registered investment advisors, funds and BDCs under federal securities law

source
stated

Relationship graph · 1710 connections

regulates
1435
regulated by
232
Employs
14
subsidiary of
5
Covered by
4
contracted by
4
files with
3
governs
2
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com